Vir Biotechnology, Inc.

NASDAQ:VIR

Biotechnology

Healthcare
$9.15 -2.63%

-$0.25 today

Market cap
$1.57B
Beta
1.64
P/E (TTM)
-3.0
EPS (TTM)
-$3.00
52W Low $4.16High $11.66

Volume 2.15M

Average 1.76M

VIR Net Income

Bottom-line profit after all expenses, interest, and taxes.

Vir Biotechnology, Inc.NASDAQ: VIR

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$125.7M, compared with -$120.97M a year earlier. Trailing-twelve-month net income was -$442.72M.

Context

  • Net income amounted to 638.9% of revenue in FY2025, down 64.5 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of -$178.94M (+59.1%) for the fiscal year ending Dec 2026, a step up from the +16.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$125.7M-192.8% QoQ
Last fiscal yearDec 2025
-$437.99M+16.1% YoY
LTMMar 2026
-$442.72M+23.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.9%+150.7%+154.7 pp
1 year+16.1%+59.1%+43.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(437.99M) USD
Year-over-year change
+16.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How VIR compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +23.4% is the 4th highest of 10, against a peer median of -21.5%.
  • Net income amounts to 676.0% of revenue for VIR, versus a peer median of 74.0%.
VIR Competitors
Net Income for VIR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABUSArbutus Biopharma CorporationLTM Mar 2026$160.72M USD+309.9%—84.0%
ASMBAssembly Biosciences, Inc.LTM Mar 2026-$6.38M USD+84.0%—9.0%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-$61.98M USD+35.7%—89.6%
NVAXNovavax, Inc.LTM Mar 2026-$87.84M USD-118.3%—14.7%
VALNValneva SELTM Mar 2026-€138.03M EUR-71.7%—88.3%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$169.52M USD-21.5%——
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026-$384.67M USD-977.2%—40.9%
VIRVir Biotechnology, Inc.LTM Mar 2026-$442.72M USD+23.4%—676.0%
BNTXBioNTech SELTM Jun 2026-€1.69B EUR-390.8%—64.0%
MRNAModerna, Inc.LTM Sep 2026-$2.79B USD+10.5%—110.5%
Peer median (excluding VIR) —-21.5%—74.0%

Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.1B1.62B86.18M74.21M68.56M
Cost of Revenue513.87M620.97M572.83M478.65M11.71M
Gross Profit581.54M994.83M(486.65M)(404.44M)56.85M
Gross Margin53.1%61.6%-564.7%-545.0%82.9%
Research & Development448.01M474.65M579.72M506.5M432.8M
Selling, General & Admin000092.07M
Operating Expenses160.79M161.76M197.66M182.73M524.87M
Depreciation & Amortization5.81M6.78M19.45M14.56M11.68M
EBITDA555.61M761.06M(641.64M)(508.91M)(426.09M)
EBITDA Margin50.7%47.1%-744.5%-685.8%-621.5%
Operating Income420.75M833.07M(684.31M)(587.17M)(468.02M)
Operating Margin38.4%51.6%-794.0%-791.3%-682.7%
Interest Income439K28.09M86.99M71.81M40.24M
Interest Expense00000
Other Income / Expenses129.05M(78.79M)56.11M64.06M30.25M
Income Before Tax549.8M754.28M(628.19M)(523.11M)(437.77M)
Pre-Tax Margin50.2%46.7%-728.9%-704.9%-638.6%
Income Tax Expense21.22M238.44M(13.08M)(1.15M)217K
Net Income528.58M515.84M(615.06M)(521.96M)(437.99M)
Net Margin48.3%31.9%-713.7%-703.4%-638.9%
EPS (Basic)4.073.89(4.59)(3.83)(3.16)
EPS (Diluted)3.963.83(4.59)(3.83)(3.16)
Weighted Avg Shares129.88M132.61M134.13M136.25M138.52M
Weighted Avg Shares (Diluted)133.44M134.81M134.13M136.25M138.52M

Vir Biotechnology, Inc.

NASDAQ:VIR

Intrinsic Alpha fair value

Locked

Current Price

$9.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.